Generation of donor-specific Tr1 cells to be used after kidney transplantation and definition of the timing of their in vivo infusion in the presence of immunosuppression

[1]  Estefania Nova Lamperti,et al.  Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells , 2016, Haematologica.

[2]  Andrew Bushell,et al.  Hurdles in therapy with regulatory T cells , 2015, Science Translational Medicine.

[3]  A. Secchi,et al.  Generation of Donor-specific T Regulatory Type 1 Cells From Patients on Dialysis for Cell Therapy After Kidney Transplantation , 2015, Transplantation.

[4]  M. Roncarolo,et al.  Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells , 2013, Front. Immunol..

[5]  J. Millis,et al.  Challenges in cryopreservation of regulatory T cells (Tregs) for clinical therapeutic applications. , 2013, International immunopharmacology.

[6]  Clelia Di Serio,et al.  Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells , 2013, Nature Medicine.

[7]  E. Geissler.  The ONE Study compares cell therapy products in organ transplantation: introduction to a review series on suppressive monocyte-derived cells , 2012, Transplantation research.

[8]  N. Tchao,et al.  Lymphodepletion and Homeostatic Proliferation: Implications for Transplantation , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  C. Paties,et al.  Molecular and functional characterization of allogantigen-specific anergic T cells suitable for cell therapy , 2010, Haematologica.

[10]  E. Hauben,et al.  Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. , 2010, Blood.

[11]  R. Eckstein,et al.  Optimization of leukocyte collection and monocyte isolation for dendritic cell culture. , 2010, Transfusion medicine reviews.

[12]  I. Joosten,et al.  Clinical Grade Treg: GMP Isolation, Improvement of Purity by CD127pos Depletion, Treg Expansion, and Treg Cryopreservation , 2008, PloS one.

[13]  M. Atkinson,et al.  Assessing the In Vitro Suppressive Capacity of Regulatory T Cells , 2007, Immunological investigations.

[14]  G. Singh.  Determination of Cutoff Score for a Diagnostic Test , 2006 .

[15]  G. Ehninger,et al.  Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study. , 2003, Journal of hematotherapy & stem cell research.

[16]  S. Burdach,et al.  Efficacy of dendritic cell generation for clinical use: recovery and purity of monocytes and mature dendritic cells after immunomagnetic sorting or adherence selection of CD14+ starting populations. , 2003, Journal of hematotherapy & stem cell research.

[17]  G. Schuler,et al.  Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. , 1999, Journal of immunological methods.

[18]  J. D. de Vries,et al.  Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells , 1996, The Journal of experimental medicine.

[19]  M. Battaglia,et al.  Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. , 2014, Current topics in microbiology and immunology.

[20]  M. Atkinson,et al.  Antigen-specific dependence of Tr 1-cell therapy in preclinical models of islet transplantation Running title : Tr 1-cell therapy in islet transplantation , 2009 .